Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
The Board of Directors unanimously recommends the shareholders to accept the offer.
Press releases
NeuroVive completes 10 percent acquisition of Isomerase Therapeutics
Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...
NeuroVive buys stake in Isomerase Therapeutics
Lund, Sweden, 14 January 2016 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the partial acquisition of British company Isomerase Therapeutics ("Isomerase") with t ...